Effects of Tirzepatide on the Clinical and Symptom Burden of Patients with Heart Failure and a Preserved Ejection Fraction, Results from the SUMMIT Trial

被引：0
|
作者：
Zile, Michael [1 ]
机构：
[1] Med Univ South Carolina, Charleston, SC USA
来源：
CIRCULATION | 2024年 / 150卷 / 25期
关键词：
Heart failure; adult; Disease management; Obesity;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4171291
引用
收藏
页码：E746 / E746
页数：1
相关论文
共 50 条
  • [1] Tirzepatide for Patients With Heart Failure With Preserved Ejection Fraction and Obesity: the SUMMIT Trial
    Packer, Milton
    CIRCULATION, 2024, 150 (25) : E714 - E714
  • [2] Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity
    Zile, Michael R.
    Borlaug, Barry A.
    Kramer, Christopher M.
    Baum, Seth J.
    Litwin, Sheldon E.
    Menon, Venu
    Ou, Yang
    Weerakkody, Govinda J.
    Hurt, Karla C.
    Kanu, Chisom
    Murakami, Masahiro
    Packer, Milton
    SUMMIT Trial Study Grp
    CIRCULATION, 2025, 151 (10) : 656 - 668
  • [3] Effects of Tirzepatide on Cardiorenal End-Organ Damage in Heart Failure and Preserved Ejection Fraction: Insights from the SUMMIT trial
    Borlaug, Barry
    CIRCULATION, 2024, 150 (25) : E737 - E737
  • [4] Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity
    Packer, Milton
    Zile, Michael R.
    Kramer, Christopher M.
    Baum, Seth J.
    Litwin, Sheldon E.
    Menon, Venu
    Ge, Junbo
    Weerakkody, Govinda J.
    Ou, Yang
    Bunck, Mathijs C.
    Hurt, Karla C.
    Murakami, Masahiro
    Borlaug, Barry A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2024,
  • [5] Reaching the SUMMIT? Benefits and potential risks associated with the use of tirzepatide in heart failure with preserved ejection fraction
    Hellenkamp, Kristian
    Sato, Ryosuke
    von Haehling, Stephan
    MED, 2025, 6 (02): : 1 - 4
  • [6] Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial
    Borlaug, Barry A.
    Zile, Michael R.
    Kramer, Christopher M.
    Baum, Seth J.
    Hurt, Karla
    Litwin, Sheldon E.
    Murakami, Masahiro
    Ou, Yang
    Upadhyay, Navneet
    Packer, Milton
    NATURE MEDICINE, 2025, 31 (02) : 544 - 551
  • [7] EMPAGLIFLOZIN IN HEART FAILURE WITH A PRESERVED EJECTION FRACTION ≥50%: RESULTS FROM THE EMPEROR-PRESERVED CLINICAL TRIAL
    Yousef, Zaheer
    HEART, 2022, 108 : A79 - A80
  • [8] Empagliflozin in Heart Failure With a Preserved Ejection Fraction ≥50% - Results From the EMPEROR-Preserved Clinical Trial
    Anker, Stefan D.
    CIRCULATION, 2021, 144 (25) : E571 - E572
  • [9] Mode of Death in Patients With Heart Failure and a Preserved Ejection Fraction Results From the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) Trial
    Zile, Michael R.
    Gaasch, William H.
    Anand, Inder S.
    Haass, Markus
    Little, William C.
    Miller, Alan B.
    Lopez-Sendon, Jose
    Teerlink, John R.
    White, Michel
    McMurray, John J.
    Komajda, Michel
    McKelvie, Robert
    Ptaszynska, Agata
    Hetzel, Scott J.
    Massie, Barry M.
    Carson, Peter E.
    CIRCULATION, 2010, 121 (12) : 1393 - 1405
  • [10] Mode of death in patients with heart failure and a preserved ejection fraction: results from irbesartan heart failure with preserved ejection fraction study (I-Preserve) trial
    Zile, M. R.
    Gaasch, W. H.
    Anand, I.
    Haass, M.
    Little, W. C.
    Miller, A.
    Lopez-Sendon, J.
    Teerlink, J. R.
    White, M.
    Carson, P. E.
    EUROPEAN HEART JOURNAL, 2009, 30 : 867 - 867
12345